Blackbird Bioventures

Advisory board member and co-founder of Hatteras Venture Partners, which he helped grow to over $850 million across seven funds. Co-founded eight life sciences companies; holds a Master of Public Policy from Harvard.

CEO of Blackbird Laboratories and Managing Director of Blackbird BioVentures. Previously COO of Scripps Research and its drug discovery division Calibr, which he helped launch and run for a decade; earned a PhD in Chemistry at Columbia University.

Venture Partner focused on opportunity identification, scientific development, and NewCo formation. Previously Head of Muscle Biology at ReNAgade Therapeutics and held preclinical roles at Fulcrum Therapeutics; holds a PhD in Human Physiology from Boston University.

Venture Partner responsible for project management, NewCo leadership, and scientific diligence. Previously at Foresite Capital and held roles at Ophthotech and the Critical Path Institute, starting his career as a medicinal chemist at Merck; holds a PhD in Organic Chemistry from Harvard University.

Venture Partner responsible for new company creation, scientific diligence, and translational projects. Previously at Foresite Capital and an Executive Director at Merck Research Laboratories; holds an MD from Cornell and a PhD in Genetics from Rockefeller University.

Venture Partner focused on creating new therapeutic ventures. Co-founded and served as President of TriBiotica LLC, an oncology company, and previously worked at CytoCure and ACGT; earned a Biology degree from the University of Wisconsin-Madison.

Venture Partner building biotechnology companies. Founder and former CEO of New Equilibrium Biosciences and previously worked at XtalPi; holds a PhD in Computational Biology from the University of Pittsburgh and Carnegie Mellon University.

Advisory and steering board member and Partner at Stepstone Group leading healthcare sourcing and diligence across fund, direct, and secondary investments. Previously at Domain Associates and Esprit Pharma; holds an MBA from Darden.

Advisory board member and Partner at Bain Capital Life Sciences since 2018. Previously a Partner at McKinsey; holds an MD from Johns Hopkins.

Office Manager supporting operational and administrative functions. Previously worked in operations roles focused on process improvement; earned a Computer Science degree from Bowie State University.

Senior Director of Molecular Discovery overseeing research programs. Previously a Principal Scientist at Hansoh Bio and a medicinal chemist at Constellation Pharmaceuticals; holds a PhD in Chemistry from UC Irvine.

Director of Lab Operations managing the opening of Blackbird BioHub. Co-inventor of the cancer therapeutic Cedazuridine; previously led laboratory operations at Barinthus Biopharmaceutics across North America.

Entrepreneur in Residence with over 20 years of experience across company formation and executive leadership. Has helped build nine startups and was most recently Chief Scientific Officer at Cartesian Therapeutics; previously an Institute Professor at the University of Maryland.

Advisory board member and Global Head of AbbVie Ventures, a geneticist and biochemist with expertise in company creation and venture investing across global biotech hubs.

Steering board member leading commercialization at Johns Hopkins Technology Ventures, where startups have attracted $4 billion in venture capital. A life sciences entrepreneur and investor who co-founded UpSurge; resides in Baltimore.

Advisory board member and Partner on Canaan's healthcare investment team, with numerous biotech board roles. Holds a PhD in Cellular and Molecular Physiology from Yale University.

Advisory board member, Partner and Executive Chair of the 4:59 Initiative at 5AM Ventures. Previously VP of Corporate Development at Relay Therapeutics and helped found Blueprint Medicines and Editas while at Third Rock Ventures; holds a PhD from Columbia.

Chief Business Officer overseeing business operations, investment strategy, and company formation. Previously a founding team member and Head of Corporate Development at Shoreline Biosciences and an Associate Director of Corporate Development at Scripps Research/Calibr; holds a PhD in Molecular Medicine from the University of Maryland, Baltimore.

Head of Finance and Operations overseeing finance and accounting. Previously built the finance function of an edtech startup and directed finance for the O'Neill Institute at Georgetown Law; holds an MBA from Virginia Tech.

Associate Director of Ventures supporting early drug discovery programs and partnerships. Earned a PhD in Molecular Biophysics at the Johns Hopkins School of Medicine researching ribosome quality control and mRNA decay.

Advisory board member and Managing Director of Boehringer Ingelheim Venture Fund USA investing in early-stage biotech. Previously held leadership roles in BI Pharmaceuticals research; holds a PhD in Neuropharmacology from Loyola University Chicago.

Entrepreneur in Residence and founding CEO of Aletira Therapeutics. Founder and former CEO of Avidea Technologies, which was acquired by Vaccitech (now Barinthus); holds an MD from Johns Hopkins and a PhD in Biomedical Engineering from Oxford.

Steering board member overseeing UMB's research, philanthropy, and economic development, and President of the UMB BioPark. Holds an MBA from Columbia Business School.

Advisory board member and Partner at RA Capital Management leading early-stage private investments and new company creation. Previously co-led SV Health Investors' US Biotech practice; holds an MD from Penn and an MBA from Wharton.

Chief of Staff partnering with leadership on strategy and partnerships supporting early-stage life science companies. Formerly a Biologics Scientist at the Tri-Institutional Therapeutics Discovery Institute; holds a PhD in Genetics from Albert Einstein College of Medicine.

Steering board member and founder of rDNA.ai, a biopharma consulting and AI database firm. Previously founded Bioscience Advisors and Recombinant Capital; holds an MBA from Stanford University.

Steering board member and Co-CEO of Brown Advisory, an investment management firm. Longtime Baltimore civic leader with board roles across Johns Hopkins institutions; holds a JD from the University of Virginia.

Steering board member and Managing Partner at Digitalis Ventures. Founder and former CEO of TARA Biosystems; previously Chief Strategy Officer at Harris & Harris Group; holds a PhD in Biochemical Engineering from University College London.

Advisory board member and Managing Director at Cure Ventures with three decades in life sciences. Formerly Managing Member and President of Omega Funds and founder of MVM's US operations; holds an MBA from Harvard Business School.

Advisory board member and Partner at Illumina Ventures investing in early-stage biotech combining genomics and AI. Previously a VP at Genentech and held senior roles at J&J and Merck; holds a PhD in Biochemistry from the University of Maryland.

Steering board member and President of Point Field Partners, the family office for Baltimore Ravens owner Steve Bisciotti. Previously at Brown Advisory and Venable LLP; a CFA charterholder and graduate of the University of Virginia School of Law.

Steering board member and President of the Baltimore Ravens, overseeing the organization's business operations. Previously at Monumental Sports and the Cleveland Browns; holds a JD from Harvard Law School.

Entrepreneur in Residence and computational biologist specializing in non-invasive diagnostics and liquid biopsies. Co-founder of Delfi Diagnostics; completed a PhD in biostatistics at the Johns Hopkins Bloomberg School of Public Health.

Advisory board member, Partner at Foresite Capital and CSO of Therapeutics at Foresite Labs. Previously held leadership roles at the Calibr-Skaggs Institute; holds a PhD in Chemical Biology from Scripps Research.

Director of Research Programs and Operations supporting early drug discovery programs. Formerly a Research Scientist at NIH's NCATS and a Senior Research Scientist at Reaction Biology Corporation; holds a PhD in Biochemistry and Molecular Biology from Rutgers University.